Hematology

Although vaccination status and the severity of COVID-19 infection were not correlated, the timing of vaccine administration influenced whether patients had severe COVID-19 infection.

The update followed results from the phase 1/2 EPCORE NHL-1 clinical trial evaluating the safety and preliminary efficacy of the drug, including in individuals with relapsed or refractory follicular lymphoma.

In crafting a patient-centered regimen, the convergence of expertise from physicians and pharmacists, paired with the values and preferences of patients, becomes paramount.

Pharmacies have the potential to introduce testing services, promote public health campaigns, collaborate with anemia-led clinics, and get more prescribing rights to diagnose anemia.

The review comes after phase 3 trial results that indicate an improvement in overall survival and progression-free survival, reducing the risk of disease progression and death.

The study authors suggest that future research should instead emphasize event rates and patient-reported outcomes to better evaluate the tolerability and frequency of AEs.

The acceptance comes after results from TRANSCEND CLL 004, which is the first trial to demonstrate clinical benefit with a CAR T cell therapy in patients who were previously treated for CLL or SLL.

The on-demand enzyme replacement therapy reduced acute thrombotic thrombocytopenic purpura events in patients who experience potentially fatal blood clotting.

The study findings provide the first in-depth look at the relationship between chromosomal changes in tumor cells and immune components of the tumor microenvironment.

Data show patients are willing to accept associated risks for a chance at a cure.

Leung discusses that various cancer types and drugs can cause thrombotic microangiopathy and impact kidney health and the renal complications connected to hematologic malignancies.

AI systems can detect minute anomalies often missed by the human eye, reducing false negatives.

Although the brand name manufacturer updated the label after the FDA’s request, generic manufacturers have not all followed suit.

Choice of therapy should be selected based on patient needs and conditions.

Little progress has been made in developing treatments that can help to stop Ewing sarcomas from spreading or coming back.

It is vital for health care teams to recognize the signs and symptoms of antiphospholipid syndrome and to identify the severity of a patient’s diagnosis based on their aPL profile.

Expert explains how the role of pharmacists in myelofibrosis treatment has evolved significantly over the past decade.

Ruben A. Mesa, MD, FACP, discusses the results of the SIMPLIFY-1 and MOMENTUM trials and how the data led to the approval of momelotinib to treat intermediate or high-risk myelofibrosis in adult patients with anemia.

Bosutinib (Bosulif) is indicated to treat pediatric patients with Philadelphia chromosome–positive chronic-phase chronic myelogenous leukemia that is newly diagnosed, resistant, or intolerant to previous therapy.

Most patients had improved clinical response within 90 days of receiving the dendritic cell vaccine and ASCT.

Axicabtagene ciloleucel achieved a complete metabolic response of 71% at 3 months versus 12% expected with standard of care among transplant ineligible patients with relapsed/refractory large B-cell lymphoma.

Microbubble cell separation can make next generation treatments, such as CAR T-cell therapy, more accessible.

Supplemental biologics license application is based on positive results from the phase 3 XTEND-Kids study, demonstrating highly effective bleed protection with once weekly dosing of Altuviiio for children with severe hemophilia A.

Improved classification of different lymphoma types can improve the potential of targeted therapies and help predict patient responses.

Bispecific antibodies have 2 distinct binding domains, which interact with either CD3 on T cells or a tumor-associated antigen on the tumor cell surface.

The use of base editing to generate universal, off-the-shelf CAR T cells is a promising approach for relapsed leukemia, with potential implications for the future of gene therapy.

Bispecific antibodies have offered a new treatment approach in relapsed/refractory multiple myeloma, with promising results in preclinical studies for multiple cancers and hematological malignancies.

A low dose of the combination treatment inhibited AML cell cycle and increased apoptosis.

Crovalimab achieved disease control and non-inferiority compared to eculizumab, which is the current standard-of-care for individuals with paroxysmal nocturnal hemoglobinuria.

Mezigdomide boosted T cell activity and worked in patients with multiple myeloma who were resistant to prior therapeutic agents.